Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma

Pier Luigi Zinzani, Lapo Alinari, Monica Tani, Mariapaola Fina, Stefano Pileri, Michele Baccarani

Research output: Contribution to journalArticle

Abstract

We assessed the impact of a reduced-dose (10 mg × 3/week for 4 weeks) schedule of alemtuzumab in 10 patients with pretreated cutaneous/peripheral T-cell lymphomas. The overall response rate was 60% (2 complete responses and 4 partial responses). In terms of infectious toxicity, cytomegalovirus reactivation occurred in 1 (10%) patient.

Original languageEnglish
Pages (from-to)702-703
Number of pages2
JournalHaematologica
Volume90
Issue number5
Publication statusPublished - May 2005

Keywords

  • Alemtuzumab
  • CTCL
  • Low-dose
  • PTCL

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma'. Together they form a unique fingerprint.

  • Cite this